[go: up one dir, main page]

AU6189999A - Specific therapeutic interventions obtained by interference with redistribution and/or targetting - Google Patents

Specific therapeutic interventions obtained by interference with redistribution and/or targetting

Info

Publication number
AU6189999A
AU6189999A AU61899/99A AU6189999A AU6189999A AU 6189999 A AU6189999 A AU 6189999A AU 61899/99 A AU61899/99 A AU 61899/99A AU 6189999 A AU6189999 A AU 6189999A AU 6189999 A AU6189999 A AU 6189999A
Authority
AU
Australia
Prior art keywords
targetting
redistribution
interference
specific therapeutic
therapeutic interventions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61899/99A
Inventor
Per O. G. Arkhammar
Sara Petersen Bjorn
Kurt Marshall Scudder
Bernard Robert Terry
Ole Thastrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioImage AS
Original Assignee
BioImage AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioImage AS filed Critical BioImage AS
Publication of AU6189999A publication Critical patent/AU6189999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
AU61899/99A 1998-10-15 1999-10-15 Specific therapeutic interventions obtained by interference with redistribution and/or targetting Abandoned AU6189999A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA199801323 1998-10-15
DKPA199801321 1998-10-15
DKPA199801322 1998-10-15
DKPA 1998-11-11
PCT/DK1999/000567 WO2000023091A2 (en) 1998-10-15 1999-10-15 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases

Publications (1)

Publication Number Publication Date
AU6189999A true AU6189999A (en) 2000-05-08

Family

ID=27221225

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61899/99A Abandoned AU6189999A (en) 1998-10-15 1999-10-15 Specific therapeutic interventions obtained by interference with redistribution and/or targetting

Country Status (5)

Country Link
EP (1) EP1146888A2 (en)
JP (1) JP2003526608A (en)
AU (1) AU6189999A (en)
CA (1) CA2346937A1 (en)
WO (1) WO2000023091A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19950647A1 (en) * 1999-10-21 2001-04-26 Merck Patent Gmbh Benzopyranoimidazolone and benzothiopyranoimidazolone derivatives as phosphodiesterase-VII inhibitors useful for treatment of e.g. asthma, psoriasis, osteoporosis, cachexia, sepsis, tumors and AIDS
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
BR0213817A (en) 2001-11-02 2004-10-19 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
JP2006500068A (en) * 2002-09-25 2006-01-05 デコード ジェネティクス イーエッチエフ. Human stroke susceptibility gene; therapy
MXPA05009242A (en) * 2003-03-17 2006-04-18 Pfizer Prod Inc Treatment of type 1 diabetes with pde5 inhibitors.
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
UA115057C2 (en) 2012-04-25 2017-09-11 Такеда Фармасьютікал Компані Лімітед Nitrogenated heterocyclic compound
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
JP6280912B2 (en) 2013-03-14 2018-02-14 武田薬品工業株式会社 Heterocyclic compounds
JP6427491B2 (en) 2013-07-03 2018-11-21 武田薬品工業株式会社 Heterocyclic compounds
ES2950424T3 (en) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Amide compound
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN111107866A (en) * 2017-06-12 2020-05-05 黑曜石疗法公司 PDE5 compositions and methods for immunotherapy
WO2018237323A1 (en) * 2017-06-23 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Pde5a destabilizing domains
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916806D0 (en) * 1989-07-22 1989-09-06 Univ Wales Medicine Modified proteins
WO1998008955A1 (en) * 1996-08-26 1998-03-05 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase [ikk] signalsome
WO1998037228A1 (en) * 1997-02-25 1998-08-27 The Regents Of The University Of California IλB KINASE, SUBUNITS THEREOF, AND METHODS OF USING SAME
AU6820998A (en) * 1997-04-07 1998-10-30 Bioimage A/S A method for extracting quantitative information relating to an influence on a cellular response
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods

Also Published As

Publication number Publication date
EP1146888A2 (en) 2001-10-24
JP2003526608A (en) 2003-09-09
WO2000023091A2 (en) 2000-04-27
WO2000023091A3 (en) 2000-07-13
CA2346937A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
AUPO203996A0 (en) Therapeutic uses
AU3891299A (en) Combination therapy for treatment of depression
AU6189999A (en) Specific therapeutic interventions obtained by interference with redistribution and/or targetting
AU2463099A (en) Gabapentin and its derivatives for the treatment of muscular and skeletal pain
AU715620C (en) Therapeutic methods and uses
AU6246199A (en) Human interleukin-b50, therapeutic uses
AU1082299A (en) Manure treatment system
AU1184399A (en) Therapeutic molecules
AU2587399A (en) Human transport-associated molecules
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU4443599A (en) Therapeutic bed
AU4629399A (en) Substituted piperazones and their therapeutic uses
AU1940800A (en) Combination therapy for the treatment of sepsis
AU2566201A (en) Compounds and methods for the treatment of pain
AUPP263498A0 (en) Novel therapeutic molecules and uses therefor
AU3300397A (en) Cyclin-c variants, and diagnostic and therapeutic uses thereof
AU4916699A (en) 4-phenyl- and 4,5-diphenylimidazole derivatives, preparation and therapeutic application
AU5005099A (en) Benzoquinolizidine and benzoindolizidine derivatives and therapeutic uses thereof
AU2420201A (en) Compounds and methods for the treatment of pain
AU5524399A (en) Inorgasmia treatment
AU6404698A (en) Treatment methods for obtaining therapeutic products and resulting products
EP1150967A4 (en) Therapeutic compounds and methods
AUPQ164599A0 (en) Therapeutic compounds and methods
AUPP973199A0 (en) Therapeutic compounds and methods
AUPQ037399A0 (en) Novel compounds and therapeutic methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase